New Developments in the Presentation, Pathogenesis, Epidemiology and Prevention of Bronchopulmonary Dysplasia

The Newborn Lung: Neonatology Questions and Controversies

Volumn , Issue , 2008, Pages 187-207

  Sosenko, Ilene R S ^a   Bancalari, Eduardo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882483522     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141603166-6.10009-9     Document Type: Chapter

References (129)

1. E Bancalari, N Claure and IRS Sosenko (2003) Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 8 63-71
2. WH Northway Jr, RC Rosan and DY Porter (1967) Pulmonary disease following respirator therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 276 357-368
3. A Gonzalez, IRS Sosenko, J Chandar, et al. (1996) Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 128 470-478
4. I Hyde, ER English and JA Williams (1989) The changing pattern of chronic lung disease of prematurity. Arch Dis Child 64 448-451
5. M McCubbin, EE Frey, JS Wagener, et al. (1989) Large airway collapse in bronchopulmonary dysplasia. J Pediatr 114 304-307
6. RW Miller, P Woo, RK Kellman and TS Slagle (1987) Tracheobronchial abnormalities in infants with bronchopulmonary dysplasia. J Pediatr 111 779-782
7. JR Groothuis, KM Gutierrez and BA Lauer (1988) Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 82 199-203
8. JJ Coalson (2003) Pathology of chronic lung disease of early infancy. RJ Bland, JJ Coalson,(Eds) Chronic lung disease in early infancy New York: Marcel Dekker 85-124
9. AN Husain, NH Siddiqui and JT Stocker (1998) Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Human Pathol 29 710-717
10. C De Felice, G Latini, S Parrini, et al. (2004) Oral mucosal microvascular abnormalities: an early marker of bronchopulmonary dysplasia. Pediatr Res 56 927-931
11. KD Wenstrom, WW Andrews, JC Hauth, et al. (1998) Elevated second trimester amniotic fluid interleukin-6 levels predict preterm delivery. Am J Obstet Gynecol 178 546-550
12. DH Watts, MA Krohn, SL Hillier and DA Eschenbach (1992) The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet Gynecol 79 351-357
13. KL Watterberg, SM Demers, SM Scott and S Murphy (1996) Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97 210-215
14. BH Yoon, R Romero, JK Jun, et al. (1997) Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-a, interleukin-lß, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 177 825-830
15. BH Yoon, Romero, CJ Kim, et al. (1997) High expression of tumor necrosis factor-a and intereukin-6 in periventricular leukomalacia. Am J Obstet Gynecol 177 406-411
16. MR Pierce and E Bancalari (1995) The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 19 371-378
17. WM Van Waarde, F Brus, A Okken and JL Kimpen (1997) Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J 10 886-890
18. S Kotecha, R Hodge, JA Schraber, et al. (2004) Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants. Pediatr Res 55 61-68
19. BA Yoder, JJ Coalson, VT Winter, et al. (2003) Effects of antenatal colonization with Ureaplasma urealyticum on pulmonary disease in the immature baboon. Pediatr Res 54 797-807
20. AJ Lyon, J McColm, L Middlemist, et al. (1998) Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 78 F10-F14
21. XI Couroucli, SE Welty, PL Ramsay, et al. (2000) Detection of microorganisms in the tracheal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia. Pediatr Res 47 225-232
22. M Liljedahl, L Bodin and J Schollin (2004) Coagulase negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia. Acta Pediatrica 93 211-215
23. MH Sawyer, DK Edwards and SA Spector (1987) Cytomegalovirus infection and bronchopulmonary dysplasia in premature infants. Am J Dis Child 141 303-305
24. VC Smith, JA Zupancic, MC McCormick, et al. (2004) Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. J Pediatr 144 799-803
25. ER Brown, A Stark, I Sosenko, et al. (1978) Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr 92 982-984
26. W Oh, BB Poindexter, R Perritt, et al. (2005) Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 147 786-790
27. T Gerhardt and E Bancalari (1980) Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 38 96-105
28. E Varsila, M Hallman, P Venge and S Andersson (1995) Closure of patent ductus arteriosus decreases pulmonary myeloperoxidase in premature infants with respiratory distress syndrome. Biol Neonate 67 167-171
29. E Bancalari, N Claure and A Gonzalez (2005) Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 88 192-201
30. JP Shenai, F Chytil and MT Stahlman (1985) Vitamin A status of neonates with bronchopulmonary dysplasia. Pediatr Res 19 185-189
31. Y Takahashi, T Miura and K Takahashi (1993) Vitamin A is involved in maintenance of epithelial cells on the bronchioles and cells in the alveoli of rats. J Nutr 123 634-641
32. JE Tyson, LL Wright, W Oh, et al. (1999) Vitamin A supplementation for extremely low birth weight infants. N Engl J Med 340 1962-1968
33. JL Caddell (1996) Evidence for magnesium deficiency in the pathogenesis of bronchopulmonary dysplasia. Magnesium Res 9 205-216
34. HS Falciglia, JR Johnson, J Sullivan, et al. (2003) Role of antioxidant nutrients and lipid peroxidation in premature infants with respiratory distress syndrome and bronchopulmonary dysplasia. Am J Perinatol 20 97-107
35. U Merz, T Peschgens, W Dott and H Hornchen (1998) Selenium status and bronchopulmonary dysplasia in premature infants. Zeit Geburt Neonatol 202 203-206
36. SL Goldman, T Gerhardt, R Sonni, et al. (1983) Early prediction of chronic lung disease by pulmonary function testing. J Pediatr 102 613-617
37. SE McGowan, AJ Holmes and J Smith (2004) Retinoic acid reverses the airway hyperresponsiveness but not the parenchymal defect that is associated with vitamin A deficiency. Am J Physiol Lung Cell Mol Physiol 286 L437-L444
38. P Groneck, B Gotze-Speer, M Oppermann, et al. (1994) Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 93 712-718
39. BG Nickerson and LM Taussig (1980) Family history of asthma in infants with bronchopulmonary dysplasia. Pediatrics 65 1140-1144
40. MH Manar, MR Brown, TW Gauthier, et al. (2004) Association of glutathione-S-transferase-P1 polymorphisms with bronchopulmonary dysplasia. J Perinatol 24 30-35
41. V Bandari, MJ Bizzaro, A Shetty, et al. (2006) Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 117 1901-1906
42. KL Watterberg, SM Scott, C Backstrom, et al. (2000) Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. Pediatrics 105 320-324
43. KL Watterberg, JS Gerdes, KL Gifford and HM Lin (1999) Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 104 1258-1263
44. KL Watterberg, JS Gerdes, CH Cole, et al. (2004) Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114 1649-1657
45. KM Silvers, AT Gibson, JM Russell and HJ Powers (1998) Antioxidant activity, packed cell transfusions and outcome in premature infants. Arch Dis Child Fetal Neonat Ed 78 F214-F219
46. KJ Collard, S Godeck and JE Holley (2005) Blood transfusion and pulmonary lipid peroxidation in ventilated premature babies. Pediatr Pulmonol 39 257-261
47. EA Ozer, A Kumral, E Ozer, et al. (2005) Effects of erythropoietin on hyperoxic lung injury in neonatal rats. Pediatr Res 58 38-41
48. G Goi, C Bairati, L Massaccesi, et al. (1998) Lysosomal enzymes in preterm infants with bronchopulmonary dysplasia: a potential diagnostic marker. Clin Chim Acta 278 23-34
49. PL Ramsay, E O'Brian Smith, E Hegemier and SE Welty (1998) Early clinical markers for the development of bronchopulmonary dysplasia: soluble E-selectin and ICAM-1. Pediatrics 102 927-932
50. JO Niu, UK Munshi, MM Siddiq and LA Parton (1998) Early increase in endothelin-1 in tracheal aspirates of preterm infants: correlation with bronchopulmonary dysplasia. J Pediatr 132 965-970
51. N Ambalavanan and ZE Novak (2003) Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates. Pediatr Res 53 240-244
52. C Danan, ML Franco, PH Jarreau, et al. (2002) High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia. Am J Resp Crit Care Med 165 1384-1387
53. ZH Aghai, R Areval, L Lumicao, et al. (2002) Basement membrane biomarkers in very low birth weight premature infants: association with length of NICU stay and bronchopulmonary dysplasia. Biol Neonate 81 16-22
54. A Cullen, LJ Van Marter, EN Allred, et al. (2002) Sunday ME. Urine bombesin-like peptide elevation precedes clinical evidence of bronchopulmonary dysplasia. Am J Resp Crit Care Med 165 1093-1097
55. A Lemons, CR Bauer, W Oh, et al. (2001) Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 107 1-8
56. W Kendig, RH Notter, C Cox, et al. (1988) Surfactant replacement therapy at birth: final analysis of a clinical trial and comparisons with similar trials. Pediatrics 82 756-762
57. AH Jobe (1993) Pulmonary surfactant therapy. N Engl J Med 328 861-868
58. RM Schwartz, AM Luby, JW Scanlon and RJ Kellogg (1994) Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500–1500 g. N Engl J Med 330 1476-1480
59. RA Parker, M Pagano and EN Allred (1992) Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia. Pediatrics 90 663-668
60. RL Goldberg and DJ Rouse (1998) Prevention of premature birth. N Engl J Med 339 313-320
61. PJ Meis, M Klebanoff, E Thom, et al. (2003) Prevention of recurrent preterm delivery by 17-a-hydroxyprogesterone caproate. N Engl J Med 348 2379-2385
62. LJ Van Marter, A Leviton, CKC Kuban, et al. (1990) Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics 86 331-336
63. LJ Van Marter, et al. (2001) Antenatal glucocorticoid treatment does not reduce chronic lung disease among preterm infants. J Pediatr 138 198-202
64. P Crowley (1995) Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972–1994. Am J Obstet Gynecol 173 322-335
65. OD Saugstad (2003) Bronchopulmonary dysplasia: oxidative stress and oxidants. Semin Neonatol 8 29-38
66. OD Saugstad, T Rootwelt and O Aalen (1998) Resuscitation of asphyxiated newborn infants with room air or oxygen: an international controlled trial: the Resair 2 study. Pediatrics 102 e1-e7
67. Collaborative European Multicenter Study Group (1988) Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82 683-691
68. AH Jobe (1993) Pulmonary surfactant therapy. N Engl J Med 328 861-868
69. RM Schwartz, et al. (1994) Effect of surfactant on morbidity, mortality and resource use in newborn infants weighing 500 to 1500 grams. N Engl J Med 330 1476-1480
70. ME Avery, WIJ Tooley, JB Keller, et al. (1987) Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 79 26-30
71. LJ Van Marter, EN Allred, M Pagano, et al. (2000) Do clinical markers of barotraumas and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The neonatology committee for the developmental nework. Pediatrics 105 1194-1201
72. PG Woodgate and MW Davies (2001) Permissive hypercapnea for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev w CD002061
73. SE Courtney, DJ Durand, JM Asselin, et al. (2002) High frequency oscillatory ventilation versus conventional mechanical ventilation for very low birth weight infants. N Engl J Med 347 643-652
74. AH Johnson, JL Peacock, A Greenough, et al. (2002) High frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 347 633-642
75. A Schulze and E Bancalari (2001) Proportional assist ventilation in infants. Clin Perinatol 28 561-578
76. SK Sinha, SM Donn, J Gavey, et al. (1997) Randomised trial of volume controlled versus time cycled, pressure limited ventilation in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 77 F202-F205
77. I Cheema and J Ahluwalia (2001) Feasibility of tidal volume-guided ventilation in newborn infants: a randomized crossover trial using the volume guarantee modality. Pediatrics 107 1323-1328
78. ZC Reyes, N Claure, MK Tauscher, et al. (2006) Randomized, controlled trial comparing synchronized intermittent mandatory ventilation and synchronized intermittent mandatory ventilation plus pressure support in preterm infants. Pediatrics 118 1409-1417
79. B Lemyre, PG Davis and AG De Paoli (2006) Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for apnea of prematurity. Cochrane Database of Systematic Reviews 2 CD002272
80. STOP-ROP Multicenter Study Group (2000) Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial. I: Primary outcomes. Pediatrics 105 295-310
81. LM Askie, DJ Henderson-Smart, L Irwig and JM Simpson (2003) Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349 959-967
82. JM Davis, RB Parad, T Michele, et al. (2003) North American Recombinant Human CuZn SOD Study Group. Pediatrics 111 469-476
83. KI Sandberg, V Fellman, L Stigson and et al (2004) N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 86 275-279
84. GA Russell and RW Cooke (1995) Randomised controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonat Ed 73 F27-F31
85. RB Cotton, TA Hazinski, JD Morrow, et al. (2006) Cimetadine does not prevent lung injury in newborn premature infants. Pediatr Res 59 795-800
86. LY Chang, M Subramaniam, BA Yoder, et al. (2003) A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Resp Crit Care Med 167 57-64
87. L Frank (1991) Hyperoxic inhibition of newborn rat lung development: protection by deferoxamine. Free Rad Biol Med 11 341-348
88. CF Potter, IA Dreshaj, MA Haxhie, et al. (1997) Effects of exogenous and endogenous nitric oxide on the airway and tissue components of lung resistance in the newborn piglet. Pediatr Res 41 886-891
89. MD Screiber, K Gat-Mestan, JD Marks, et al. (2003) Inhaled nitric oxide in premature infants with respiratory distress syndrome. N Engl J Med 349 2099-2107
90. KP Van Meurs, LL Wright, RA Ehrenkranz, et al. (2005) Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353 82-84
91. JP Kinsella, GR Cutter, WF Walsh, et al. (2006) Early inhaled nitric oxide in premature newborns with respiratory failure. PAS Late-breaker abstract 1
92. RA Ballard, WE Truog, RJ Martin, et al. (2006) Improved outcome with inhaled nitric oxide in preterm infants mechanically ventilated at 7–21 days of age. PAS Late-breaker abstract 2
93. EF Bell and MJ Acarregui (2001) Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants Cochrane Review. Cochrane Library 3 CD000503
94. ML Blakely, KA Kennedy, KP Lally and JE Tyson (2002) Intravenous indomethacin for symptomatic patent ductus arteriosus in preterm infants. The Cochrane Database of Systematic Reviews 1 CD003479
95. B Schmidt, RS Roberts, A Fanaroff, et al.,. and the TIPP investigators (2006) Indomethacin prophylaxis, patent ductus arteriosus and the risk of bronchopulmonary dysplasia: further analyses from the trial of indomethacin prophylaxis in preterms (TIPP). J Pediatr 148 730-734
96. L Frank and EE Groseclose (1982) Oxygen toxicity in newborns: the adverse effects of undernutrition. J Appl Physiol 53 1248-1255
97. SC Langley and FJ Kelly (1992) Effect of food restriction on hyperoxia-induced lung injury in preterm guinea pig. Am J Physiol Lung 263 L357-L362
98. SM Deneke, SN Gershoff and BL Fanberg (1983) Potentiation of oxygen toxicity in rats by dietary protein or amino acid deficiency. J Appl Physiol 54 147-151
99. TL Dormandy (1969) Biological rancidification. Lancet 2 684-686
100. IRS Sosenko, SM Innis and Frank (1988) Polyunsaturated fatty acids and protection of newborn rats from oxygen toxicity. J Pediatr 112 630-637
101. IRS Sosenko, SM Innis and L Frank (1991) Intralipid increases lung polyunsaturated fatty acids and protects newborn rats from oxygen toxicity. Pediatr Res 30 413-417
102. C Hammerman and MJ Aramburo (1988) Decreased lipid intake reduces morbidity in sick, premature neonates. J Pediatr 113 1083-1088
103. N Gilbertson, IZ Kovar, DJ Cox, et al. (1991) Introduction of intravenous loipi administration on the first day of life in the very low birth weight neonate. J Pediatr 119 615-623
104. IRS Sosenko, M Rodriguez-Pierce and E Bancalari (1993) Effect of early initiation of intravenous lipid administration on the incidence and severity of chronic lung disease. J Pediatr 123 975-982
105. KG Brownlee, E Kelly, PC Ng, et al. (1993) Early or late parenteral nutrition for the sick preterm infant? Arch Dis Child 69 281-283
106. MH Alwaidh, L Bowden, B Shaw and SW Ryan (1996) Randomised trial of effect of delayed intravenous lipid administration on chronic lung disease in preterm neonates. J Pediatr Gastro Nutr 22 303-306
107. O Pitkanen, M Hallman and S Anderson (1991) Generation of free radicals in lipid emulsion used in parenteral nutrition. Pediatr Res 29 56-59
108. M Rudiger, A von Baehr, R Haupt, et al. (2000) Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 28 1572-1577
109. M Hallman, K Bry, K Hoppu, et al. (1992) Inositol supplementation in premature infants with respiratory distress. N Engl J Med 326 1233-1239
110. A Howlett and A Ohlsson (2000) Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 4 CD000366
111. EM Widdowson (1980) Chemical composition and nutritional needs of the fetus at different stages of gestation. H Aebi, R Whitehead,(Eds) Maternal nutrition during pregnancy and lactation Berne: H Huber 39-48
112. VA Husted, GR Gutcher, SA Anderson, et al. (1984) Relationships of vitamin A (retinol) status and lung disease in the preterm infant. J Pediatr 105 610-615
113. JP Shenai, F Chytil, A Jhaveri, et al. (1981) Plasma vitamin A and retinol-binding protein in premature and term infants. J Pediatr 99 302-305
114. JE Tyson, LL Wright, W Oh, et al. (1999) Vitamin A supplementation for extremely low birth weight infants: National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 340 1962-1968
115. N Ambalavanan, JE Tyson, KA Kennedy, et al. (2005) National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 115 e249-e254
116. BA Darlow and PJ Graham (2002) Vitamin A supplementation for preventing morbidity and mortality in very low birth weight infants. Cochrane Database Syst Rev 4 CD000501
117. N Ambalavanan, KA Kennedy, JE Tyson and WA Carlo (2004) Survey of vitamin A supplementation for extremely low birth weight infants: is clinical practice consistent with evidence? J Pediatr 145 304-307
118. Halliday HL, Ehrenkranz RA. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Oxford: The Cochrane Library; 2001; Update Software: 3
119. Halliday HL, Ehrenkranz RA. Moderately early postnatal (7–14 days) corticosteroids for preventing chronic lung disease in preterm infants. Oxford: The Cochrane Library; 2001; Update Software: 3
120. Halliday HL, Ehrenkranz RA. Delayed (> 3 weeks) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Oxford: The Cochrane Library; 2001; Update Software: 3
121. DG Grier and HL Halliday (2003) Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin Neonatol 8 83-91
122. TT Wilson, L Waters, CC Patterson, et al. (2006) Neurodevelopmental and respiratory follow-up results at 7 years for children from the United Kingdom and Ireland enrolled in a randomized trial of early and late postnatal corticosteroid treatment, systemic and inhaled (the Open Study of Early Corticosteroid Treatment). Pediatrics 117 2196-2205
123. JA Stiskal, MS Dunn, AT Shennan, et al. (1998) α 1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized controlled trial. Pediatrics 1011 89-94
124. CR Levine, IH Gewolb, K Allen, et al. (2005) Safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 58 15-21
125. B Schmidt, RS Roberts, P Davis, et al. (2006) Caffeine therapy for apnea of prematurity. N Engl J Med 354 2112-2121
126. E Bancalari (2006) Caffeine for apnea of prematurity. N Engl J Med 354 2179-2181
127. SA ter Horst, GT Wagenaar, E de Boer, et al. (2004) Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 97 2014-2019
128. B Almario and IRS Sosenko (2006) Pentoxifylline improves survival, decreases lung injury and augments catalase and glutathione peroxidase activity during prolonged exposure to hyperoxia in newborn rats. PAS Abstract 5168 10
129. B Almario, S Wu, J Peng and IRS Sosenko (2006) Pentoxifylline up-regulates lung vascular endothelial growth factor (VEGF) gene expression and prolongs survival in hyperoxia-exposed newborn rats. PAS Abstract 4132 8